Incidence and predictors of new‐onset atrial fibrillation in ST‐elevation myocardial infarction: A single‐center study

Abstract

Abstract Background and Aims Atrial fibrillation (AF) is a common arrhythmia that occurs following ST‐elevation myocardial infarction (STEMI) and can significantly impact clinical outcomes. We investigated the incidence and predictors of AF following STEMI in patients, as well as its association with major adverse cardiac and cerebrovascular events (MACCE). Methods We conducted a retrospective cohort study, including all STEMI patients who presented under code 247 to Tehran Heart Center between 2016 and 2020 and completed a 1‐year follow‐up. Patients were divided into two groups based on the development of AF during follow‐up, and their baseline and clinical characteristics were compared. We used multivariable regression models to identify predictors of MACCE. Results Out of 3647 STEMI patients, 84 (2.3%) developed new‐onset AF (NOAF). Patients with AF were significantly older and had lower levels of total and low‐density lipoprotein cholesterol, triglyceride, and hemoglobin, but higher levels of fasting blood sugar and creatinine. AF patients were also more likely to have a history of hypertension, chronic kidney disease (CKD), congestive heart failure, and cerebrovascular accidents. The multivariable logistic regression model identified the CHA2DS2‐VASc score and CKD as independent predictors of NOAF following primary percutaneous coronary intervention. Furthermore, the incidence of MACCE was higher in the AF group, and AF independently predicted MACCE with a hazard ratio of 2.766. Conclusion The CHA2DS2‐VASc score and the presence of CKD can serve as useful predictors of NOAF among patients with STEMI. Early detection and appropriate management are crucial to improve outcomes.

Keywords

• atrial fibrillation
• clinical outcome
• primary percutaneous coronary intervention
• ST‐elevation myocardial infarction